Marc Sabatine, MD
Cardiovascular Disease · Boston, MANPI 1346298668
Payments from drug & device makers
Across 317 payments — averaging $98,369 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11.8M
- Merck$6.2M
- Pfizer$6.1M
- AstraZeneca$5.7M
- Astrazeneca UK Limited$687K
- Ionis Pharmaceuticals, Inc.$452K
- plus $358K from 10 others
Across 5 payments — averaging $982.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$5K
- Novartis Pharma AG$15
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 123 | $11,752,952 |
| Merck | 77 | $6,162,773 |
| Pfizer | 26 | $6,056,286 |
| AstraZeneca | 31 | $5,713,789 |
| Astrazeneca UK Limited | 28 | $686,746 |
| Ionis Pharmaceuticals, Inc. | 1 | $451,884 |
| Astrazeneca AB | 8 | $224,172 |
| Daiichi Sankyo Inc. | 2 | $70,000 |
| Novo Nordisk AS | 6 | $19,916 |
| Dr.reddy's Laboratories,inc. | 1 | $15,000 |
| Boehringer Ingelheim | 6 | $14,172 |
| Boehringer Ingelheim International GmbH | 2 | $6,025 |
| Bristol Myers Squibb | 1 | $4,165 |
| Modernatx, Inc. | 3 | $4,000 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,013 |
| Janssen Research & Development, LLC | 1 | $18 |
How this compares
$31,182,910 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boston
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Scott SolomonBoston$16.2M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Benjamin SciricaBoston$11.3M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
- Michelle OdonoghueBoston$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.